Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.
Pérez-Molina JA, Mora Rillo M, Suárez-Lozano I, Casado-Osorio JL, Teira Cobo R, Rivas González P, Pedrol Clotet E, Hernando-Jerez A, Domingo P, Barquilla Díaz E, Esteban H, González-García J; Gesida 5808 Study Group. Pérez-Molina JA, et al. Among authors: domingo p. HIV Clin Trials. 2012 May-Jun;13(3):131-41. doi: 10.1310/hct1303-131. HIV Clin Trials. 2012. PMID: 22592093
Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort).
Suárez-Lozano I, Fajardo JM, Garrido M, Roca B, García-Alcalde ML, Geijo P, Selma D, Lozano F, Teira R, Viciana P, Pérez-Cortés S, Domingo P, Menchero A, Galindo MJ, Cosín J, Ribera E, Arribas JR, Lacalle JR. Suárez-Lozano I, et al. Among authors: domingo p. AIDS. 2002 Dec 6;16(18):2496-9. doi: 10.1097/01.aids.0000042931.55529.82. AIDS. 2002. PMID: 12461432 No abstract available.
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V. Barrios A, et al. Among authors: domingo p. AIDS. 2005 Mar 24;19(6):569-75. doi: 10.1097/01.aids.0000163933.14649.93. AIDS. 2005. PMID: 15802975 Clinical Trial.
[Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)].
Teira R, Suárez-Lozano I, Muñoz P, Viciana P, Lozano F, Galindo MJ, Terrón A, Vergara A, Geijo P, Arribas JR, Cosín J, Domingo P, Ribera E, Roca B, García-Alcalde ML, Sánchez T, Muñoz-Sanz A. Teira R, et al. Among authors: domingo p. Enferm Infecc Microbiol Clin. 2005 Apr;23(4):213-7. doi: 10.1157/13073147. Enferm Infecc Microbiol Clin. 2005. PMID: 15826546 Spanish.
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA. Rodes B, et al. Among authors: domingo p. J Med Virol. 2005 Sep;77(1):23-8. doi: 10.1002/jmv.20395. J Med Virol. 2005. PMID: 16032728
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V; EFADITE Study Group. Barrios A, et al. Among authors: domingo p. Antivir Ther. 2005;10(7):825-32. Antivir Ther. 2005. PMID: 16312178 Clinical Trial.
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E; GESIDA 04/98 Study Group. Miro JM, et al. Among authors: domingo p. Clin Infect Dis. 2006 Jul 1;43(1):79-89. doi: 10.1086/504872. Epub 2006 May 31. Clin Infect Dis. 2006. PMID: 16758422 Clinical Trial.
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, García Alcalde ML, Cosín J, Terrón A, Galindo MJ, Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. Domingo P, et al. J Antimicrob Chemother. 2008 Jun;61(6):1348-58. doi: 10.1093/jac/dkn121. Epub 2008 Mar 20. J Antimicrob Chemother. 2008. PMID: 18356150 Clinical Trial.
758 results